由 KR Flaherty 著作 · 2021 · 被引用 2 次 — The primary analysis of the INBUILD trial showed that in subjects with progressive fibrosing interstitial lung diseases (ILDs), nintedanib slowed the decline in ...
確定! 回上一頁